Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder
- Trial Design
- Efficacy
- Safety
This morning, LSD drug developer Definium Therapeutics shared positive topline data from its second Phase 3 study of its lead candidate, DT120, in generalised anxiety disorder (GAD). It’s the third positive Phase 3 readout from the company since June.
Trial Design
The trial, dubbed Panorama, saw 245 participants across around 32 U.S. and international sites randomised to receive a single dose of 100 µg DT120 (N=96), placebo (N=97), or 50 µg DT120 (N=52) during a 12 week double-blind period, before entering a 40 week extension with an opportunity for...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In